Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

Contributed by: Business Wire

Logo

Tags

Biotechnology

Infectious Diseases

Health

Pharmaceutical

Oncology

Debiopharm

More Like This

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

PR Newswire associated0

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy® in Advanced Breast Cancer